Is 7-OH Getting Banned? The DEA's August 5 Schedule I Deadline, Explained (2026)

If you've searched "is 7-OH getting banned," "7-OH schedule 1," or "7-OH ban date," here is the full picture in plain language — what the DEA actually filed, the exact timeline, which products are covered, and what changes for buyers when the order takes effect. This is an educational summary of public federal documents, not legal advice, and it makes no claims about any product's effects.

What did the DEA actually announce?

On July 1, 2026, the DEA announced it had sent two Notices of Intent (NOIs) to the Federal Register. Both published on Monday, July 6, 2026:

• Docket DEA-1570 (91 FR 40917): a notice of intent to temporarily place 7-hydroxymitragynine above a specified threshold — including its isomers, esters, ethers, and salts — in Schedule I of the Controlled Substances Act. Read the breakdown of the exact numbers in the DEA's 7-OH threshold, explained.
• Docket DEA-1644 (91 FR 40909): a companion notice covering three related kratom-derived compounds by name — mitragynine pseudoindoxyl, MGM-15, and MGM-16. Details in the second DEA notice, explained.

A Notice of Intent is not the ban itself. It is the legally required first step: under 21 U.S.C. 811(h), the DEA must publish an NOI and then wait at least 30 days before issuing the actual temporary scheduling order.

When does the 7-OH ban take effect?

The NOI states it directly: "The temporary scheduling order will be published in the Federal Register on or after August 5, 2026." Thirty days from the July 6 publication lands on August 5 — the earliest legal date the order can issue. The order becomes effective the day it is published, which could be August 5 itself or any date after. There is no separate grace period once it publishes.

What does "temporary scheduling" mean?

Temporary scheduling under 21 U.S.C. 811(h) is an emergency mechanism the DEA uses when it finds a substance poses an imminent hazard to public safety. It skips the years-long formal rulemaking process, but it is time-limited: the placement lasts two years, with a possible one-year extension, while HHS and FDA complete the full scientific and medical evaluation that permanent scheduling requires. During that window, the covered material carries full Schedule I status — the same regulatory controls and administrative, civil, and criminal sanctions that apply to any Schedule I substance, covering manufacturing, distribution, import, export, and possession.

What's in scope — and what isn't

The action is written around a quantitative threshold, not the kratom plant as a whole.

In scope (Schedule I once the order takes effect):

• Kratom (Mitragyna speciosa) botanical material containing more than 0.050% 7-OH by dry weight
• Any synthetic or further-processed product — extracts, concentrates, edibles, beverages, pressed pills/tablets — containing more than 0.050% 7-OH by weight or volume, or more than 1.00 mg of 7-OH per package or article
• 7-OH's isomers, esters, ethers, salts, and salts of those forms
• By name under the companion docket: mitragynine pseudoindoxyl, MGM-15, and MGM-16

Out of scope:

• Plain kratom leaf and leaf powder below the threshold — natural leaf contains only trace 7-OH, so ordinary kratom is not being scheduled by this action
• Mitragynine itself, kratom's primary alkaloid, is not named in either notice

In practice, essentially every concentrated 7-OH tablet, powder, and shot on the market exceeds 1.00 mg per unit, so the concentrated 7-OH category as consumers know it is inside the line. The full math is covered in the threshold explainer.

What happens for buyers after the effective date?

Once the temporary order publishes, above-threshold 7-OH becomes a Schedule I controlled substance federally. For consumers, the practical effects are:

• Legitimate retailers will stop selling covered products. Manufacturing, distributing, and selling above-threshold 7-OH becomes federally unlawful, so compliant vendors will have pulled covered SKUs by the effective date.
• Possession is also covered. Schedule I controls extend to possession, not just sale. What that means for products purchased before the effective date is a question for qualified legal counsel in your state — this article is not legal advice.
• Plain kratom leaf remains federally legal. Below-threshold leaf and leaf powder are outside the action, though state kratom laws still vary.
• State law still matters. Several states restricted or banned 7-OH before this federal action; the federal date does not override earlier state rules. See 7-OH laws by state.

Is this permanent?

Not automatically. Temporary scheduling is capped at two years (plus a possible one-year extension). Making the placement permanent requires a separate, full rulemaking with a scientific and medical evaluation from HHS/FDA, public comment, and formal findings. The related HHS Request for Information — open through July 31, 2026 — is part of that evidence-gathering, and the government could adjust the threshold figures, make the scheduling permanent, let it lapse, or take a different regulatory path. Nothing about the long-term status is settled yet.

Where things stand for the category

7ohBlack is a wholesale and education-focused supplier, and our position is straightforward: this is a published federal action with a defined legal process, and the responsible move for every business in the category is to read the documents, verify COAs against the threshold, and comply. Retailers should start with the retailer compliance guide. Consumers who want to verify what they're buying can review any product's lab results in the Favor'd Alkz COA database.

Frequently asked questions

For adults 21+, where legal. This article is educational and is not legal advice; regulatory status changes quickly — verify the current Federal Register dockets and your state's law before acting. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.